시각장애 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 처방 유형별, 치료제별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Optical Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Prescription Type, By Therapeutics, By End User, By Region and Competition, 2020-2030F
상품코드:1703296
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
시각장애 치료제 세계 시장은 2024년 376억 8,000만 달러로 평가되었고, 2030년에는 603억 5,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 8.14%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.
안과 질환 또는 안질환이라고도 불리는 시각장애은 눈과 시각계에 영향을 미치는 광범위한 증상을 포함합니다. 이러한 질환은 안구 구성 요소의 구조와 기능을 손상시켜 시각 장애, 불편함 및 기타 증상을 유발합니다. 이러한 질환은 모든 연령대에 영향을 미칠 수 있으며, 경증부터 중증까지 다양한 증상을 유발할 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
376억 8,000만 달러
시장 규모 : 2030년
603억 5,000만 달러
CAGR : 2025-2030년
8.14%
급성장 부문
일반의약품
최대 시장
북미
시력장애의 치료법은 다양하며, 증상의 성격과 진행 정도에 따라 달라집니다. 교정 렌즈(안경이나 콘택트렌즈), 약리 요법(점안제나 먹는 약), 수술, 생활습관 개선, 조기 발견과 지속적인 모니터링을 위한 정기적인 안과 검사 등이 있습니다. 이러한 치료의 종합적인 목표는 시기능을 유지하고 눈의 전반적인 건강을 유지하는 것입니다.
주요 시장 성장 촉진요인
기술 발전
주요 시장 이슈
제네릭 의약품 경쟁사
주요 시장 동향
환자 중심의 치료 접근법
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 시각장애 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
처방전 유형별(시판약, 처방 안과약)
치료제별(노인황반변성, 결막염, 당뇨병성 황반부종, 당뇨병 망막증, 안구건조증, 안구암, 녹내장 등)
최종사용자별(진단센터, 안과 클리닉, 병원)
기업별(2024년)
시장 맵
제6장 아시아태평양의 시각장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제7장 유럽의 시각장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제8장 북미의 시각장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제9장 남미의 시각장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 시각장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제13장 세계의 시각장애 치료제 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
Alcon Inc.
Novartis ag
Johnson & Johnson services, Inc.
Bausch health
Merck & co. Inc.
Coherus biosciences, Inc.
Allergan
Pfizer, Inc.
Bayer ag
Santen pharmaceuticals co. Ltd.
Genetech, Inc.
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Optical Disorders Drugs Market for optical disorders drugs was valued at USD 37.68 billion in 2024 and is projected to reach USD 60.35 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.14% during the forecast period. Optical disorders, also referred to as ophthalmic or eye disorders, encompass a broad spectrum of conditions affecting the eyes and the visual system. These disorders can impair the structure or function of ocular components, leading to visual disturbances, discomfort, or additional symptoms. They can affect individuals across all age groups and vary in severity from mild to debilitating.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 37.68 Billion
Market Size 2030
USD 60.35 Billion
CAGR 2025-2030
8.14%
Fastest Growing Segment
Over-The-Counter Drugs
Largest Market
North America
Treatment options for optical disorders are diverse and depend on the nature and progression of the condition. Interventions may include corrective lenses (eyeglasses or contact lenses), pharmacological therapies (eye drops or oral medications), surgical procedures, lifestyle changes, and routine eye examinations aimed at early detection and ongoing monitoring. The overarching goal of these treatments is to preserve visual function and maintain overall ocular health.
Key Market Drivers
Technological Advancements
Recent technological progress in ophthalmology has significantly shaped the pharmaceutical landscape. One major development is the introduction of sustained-release drug delivery systems that provide controlled and extended medication release, reducing the frequency of administration. A notable example is Roche's Susvimo (ranibizumab injection), which received FDA approval in February 2025 for the treatment of diabetic macular edema (DME). It is the first and only FDA-approved therapy shown to maintain vision in DME patients with fewer treatments compared to standard care.
Nanotechnology is playing a critical role in enhancing ocular drug delivery. Nanogels and other nano-sized carriers have demonstrated improved tissue penetration and bioavailability, particularly in treating anterior segment conditions such as glaucoma, cataracts, dry eye syndrome, and bacterial keratitis.
Advancements in topical ophthalmic formulations are also contributing to market growth. For example, lipid-based eye drops have been developed to effectively manage evaporative dry eye disease by stabilizing the tear film and reducing tear evaporation.
Biotechnology has facilitated the emergence of gene therapies that target specific molecular pathways involved in various ocular diseases. These therapies have shown potential in delivering long-term visual improvements for patients suffering from inherited or degenerative retinal conditions.
Key Market Challenges
Generic Competition
The growing presence of generic drugs poses a significant challenge for brand-name pharmaceutical companies operating in the optical disorders segment. Once patent protections expire, lower-cost generics enter the market, often at substantially reduced prices, impacting revenue streams of original drug manufacturers. Patients and healthcare providers frequently opt for generics due to their affordability, leading to decreased market share for innovator products.
The rapid adoption of generics can lead to price erosion and force originator companies to reduce prices or offer discounts to maintain competitiveness. This shift adversely affects profit margins and limits the ability to reinvest in research and development (R&D). Moreover, the loss of exclusivity following patent expiry often results in diminished market dominance.
This competitive pressure can discourage pharmaceutical firms from pursuing new drug innovations in the ophthalmic space, given the reduced commercial incentives once generics become viable. As a result, companies must carefully balance R&D investments with strategic planning to mitigate the risks associated with generic competition.
Key Market Trends
Patient-Centric Treatment Approaches
There is a growing trend toward tailoring ophthalmic treatment plans to align with individual patient preferences and lifestyles. Healthcare providers are increasingly considering factors such as daily routines, treatment goals, and comfort when selecting medications and therapeutic approaches.
Patients express varied preferences for modes of drug administration-some favor eye drops, while others may opt for ointments or less frequent dosing schedules. In response, pharmaceutical companies are expanding their product portfolios to include a range of delivery formats designed for ease of use and integration into daily life.
User-friendly packaging and intuitive application mechanisms are being developed to improve adherence to treatment protocols. Additionally, reducing the occurrence of side effects is a major focus in drug development, as improved tolerability leads to higher compliance and better clinical outcomes.
Flexibility in dosing is also highly valued by patients. Drugs offering once-daily or extended dosing intervals provide greater convenience and enhance patient autonomy. The industry is further shifting toward collaborative care models, emphasizing patient education and shared decision-making between patients and healthcare providers. This approach ensures that treatment plans reflect individual values and objectives, leading to increased satisfaction and better management of eye disorders.
Key Market Players
Alcon Inc.
Novartis ag
Johnson & Johnson services, Inc.
Bausch health
Merck & co. Inc.
Coherus biosciences, Inc.
Allergan
Pfizer, Inc.
Bayer ag
Santen pharmaceuticals co. Ltd.
Genetech, Inc.
Report Scope:
In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Optical Disorders Drugs Market, By Prescription Type:
Over-The-Counter Drugs
Prescription Ophthalmic Drugs
Optical Disorders Drugs Market, By Therapeutics:
Age-Related Macular Degeneration
Conjunctivitis
Diabetic Macular Edema
Diabetic Retinopathy
Dry Eye
Eye Cancer
Glaucoma
Others
Optical Disorders Drugs Market, By End User:
Diagnostic Centers
Eye Clinics
Hospitals
Optical Disorders Drugs Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.
Available Customizations:
Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Optical Disorders Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
